Another recent randomized trial [20] of 118 patients with MRI-proven NAFLD over 72 weeks demonstrated that pemafibrate treatment improved ALT, GGT, and ALP levels as well as cirrhosis. The gene discussed is GPT; the disease is Cirrhosis.